SPTX outlines Glyph platform progress for oral neuropsychiatric therapies
SPTX presented its neuroscience pipeline, saying the Glyph platform can improve drug bioavailability and safety. Lead programs GlyphAllo and GlyphAgo target depression and anxiety, with promising clinical data and upcoming pivotal trials.
The company said its neuroscience pipeline is centered on the Glyph platform, which it described as designed to improve drug bioavailability and safety. It said lead programs GlyphAllo and GlyphAgo are aimed at depression and anxiety, and pointed to promising clinical data and upcoming pivotal trials. The company also highlighted the platform’s versatility.